Acrivon Therapeutics, Inc. (ACRV) stock
ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.56+0.13 (+9.09%)
Close on Nov 18, 2026Market cap $66.85MP/E –Yield –
Acrivon Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Acrivon Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$62.92M. For fiscal 2025 it was -$63.67M. The highest annual figure on record is -$13.98M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$63.67M | – |
| FY2024 | Dec 31, 2024 | -$65.67M | – |
| FY2023 | Dec 31, 2023 | -$42.64M | – |
| FY2022 | Dec 31, 2022 | -$30.12M | – |
| FY2021 | Dec 31, 2021 | -$13.98M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$14.86M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.54M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.24M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.36M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.08M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.37M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.36M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.35M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.52M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.42M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.63M | – |
See a number that looks wrong?